Wang, E. S., Montesinos, P., Issa, G. C., Foran, J. M., Erba, H. P., Rodríguez-Arbolí, E., Fedorov, K., Heiblig, M., Heidel, F., Altman, J. K., Baer, M. R., Adès, L., Pettit, K. M., Peterlin, P., Papayannidis, C., Zhang, Z., Riches, M., Corum, D., Leoni, M., Fathi, A. T. (2025). Ziftomenib in relapsed/refractory (R/R)
            <i>NPM1</i>
            -mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.6506